Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $67.48 USD
Change Today -0.19 / -0.28%
Volume 5.2M
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$67.87
Previous Close
$67.67
Day High
$68.08
Day Low
$67.34
52 Week High
05/20/15 - $69.86
52 Week Low
07/8/14 - $47.34
Market Cap
112.5B
Average Volume 10 Days
6.9M
EPS TTM
$1.51
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
44.6x
Dividend
$1.48
Dividend Yield
2.18%
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Expands R&D Presence Within Hubs of World Class Science and Innovation

Bristol-Myers Squibb Company announced that the evolution of the company’s R&D organization, including plans to expand its presence within hubs of scientific excellence and innovation with the opening of a new research site in Cambridge, Mass. in addition to the ongoing expansion of the company’s R&D Discovery site in the San Francisco Bay Area. The new facility in Cambridge, which will be located at 100 Binney Street in Kendall Square, is expected to open in 2018. The ongoing site expansion in the San Francisco Bay Area adds 61,000 square feet of laboratory and office space at the Woodside Technology Park life science campus and is expected to be completed in 2016.

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years. This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. Mild infusion reactions were reported in six subjects: four in the andexanet arm and two in the placebo arm. No subjects discontinued the study due to an adverse event. The full data set was presented in a Late-Breaking Clinical Trial oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto. Portola plans to submit data from the ANNEXA-A (apixaban) and ANNEXA-R (rivaroxaban) studies, and initial data from a Phase 4 study, as part of its Biologics License Application (BLA) to the FDA under an Accelerated Approval pathway by the end of 2015.

Bristol-Myers Squibb Company Announces European Commission Approves Opdivo

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. The approval allows for the marketing of Opdivo in all 28 Member States of the EU. It follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP), which was announced on April 24, 2015. This accelerated assessment was given because Opdivo qualified for the designation as a medicinal product of major interest from the point of view of public health and in particular from the view point of therapeutic innovation. Opdivo is the only PD-1 immune checkpoint inhibitor to receive an accelerated assessment in Europe, andis the first approval given by the European Commission for a PD-1 inhibitor in any cancer. The incidence of melanoma has continued to increase in almost all European countries, with an estimated one in five patients expected to develop metastatic, or advanced, disease. Historically, prognosis for late-stage metastatic melanoma has been poor: the average survival rate for stage IV is just six months with a one-year mortality rate of 75%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $67.48 USD -0.19

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Allergan plc $307.51 USD +0.60
Amgen Inc $153.26 USD -1.73
Medtronic PLC $73.81 USD -0.27
Novo Nordisk A/S kr368.70 DKK -2.20
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 50.1x
Price/Sales 7.0x
Price/Book 7.2x
Price/Cash Flow 49.9x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog
  Read More...
Bristol-Myers Squibb to open Cambridge R&D center
  Read More...
Bristol-Myers Squibb to shift research jobs
  Read More...
Bristol-Myers to Close Sites, Cut 100 Jobs
  Read More...
Bristol-Myers to stop new antiviral drug research
  Read More...
Bristol-Myers Halts Virus-Drug Research, Cuts 100 Employees
  Read More...
Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
[at noodls] - Dateline: 'Ultimately, our goal is to continue to accelerate the translation of scientific knowledge and insights into the next wave of potentially transformational medicines for patients with serious ...
  Read More...